New cocktail of drugs aims to tackle tough lung cancer
NCT ID NCT04924101
First seen Jul 01, 2026 · Last updated Jul 01, 2026
Summary
This phase 2 trial tests whether adding experimental drugs (MK-4830, boserolimab, or lenvatinib) to the standard combination of pembrolizumab and chemotherapy can improve outcomes for people with extensive-stage small cell lung cancer. Participants receive one of these new combinations as their first treatment. The study measures how many tumors shrink or disappear and how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
pembrolizumab, MK-4830, boserolimab, lenvatinib, etoposide, cisplatin, carboplatin
What this could lead to
If successful, this combination could improve response rates and delay cancer progression for people with advanced small cell lung cancer.
What could go wrong
This is an early-phase trial with no formal hypothesis testing, so results may not confirm benefit. Adding multiple drugs also raises the risk of side effects.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SMALL CELL LUNG CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Asan Medical Center-Department of Oncology ( Site 1103)
Seoul, 05505, South Korea
-
Banner MD Anderson Cancer Center ( Site 0102)
Gilbert, Arizona, 85234, United States
-
Baptist Health Lexington-Research ( Site 0108)
Lexington, Kentucky, 40503, United States
-
Cantonal Hospital St.Gallen-Oncology & Hematology ( Site 2502)
Sankt Gallen, Canton of St. Gallen, 9007, Switzerland
-
Chungbuk National University Hospital ( Site 1107)
Cheongju-si, North Chungcheong, 28644, South Korea
-
Cleveland Clinic-Taussig Cancer Center ( Site 0116)
Cleveland, Ohio, 44195, United States
-
GBUZ "SPb CRPCstmc(o)" ( Site 2705)
Saint Petersburg, Sankt-Peterburg, 197758, Russia
-
Georgia Cancer Specialists ( Site 0106)
Atlanta, Georgia, 30341, United States
-
Hamilton Health Sciences-Juravinski Cancer Centre ( Site 2003)
Hamilton, Ontario, L8V 4X2, Canada
-
Hospital Insular de Gran Canaria ( Site 2402)
Las Palmas de Gran Canaria, Las Palmas, 35001, Spain
-
Hospital Universitari Vall d'Hebron-Oncology ( Site 2401)
Barcelona, 08035, Spain
-
Instituto Catalan de Oncologia - Hospital Duran i Reynals ( Site 2403)
L'Hospitalet de Llobregat, Catalonia, 08908, Spain
-
Istituto Europeo di Oncologia IRCCS-Divisione di Oncologia Toracica ( Site 2304)
Milan, 20141, Italy
-
Jász-Nagykun-Szolnok Megyei Hetényi Géza Kórház-Onkologiai Kozpont ( Site 2800)
Szolnok, Jász-Nagykun-Szolnok, 5004, Hungary
-
Kingston Health Sciences Centre-Kingston General Hospital Site ( Site 2005)
Kingston, Ontario, K7L 2V7, Canada
-
Klinik Floridsdorf-Abteilung für Innere Medizin und Pneumologie ( Site 2100)
Vienna, 1210, Austria
-
Klinik Penzing-2. Lungenabteilung ( Site 2101)
Vienna, State of Vienna, 1140, Austria
-
Krasnoyarsk Regional Oncology Dispensary, Named after Krizhanovsky ( Site 2708)
Krasnoyarsk, Krasnoyarsk Krai, 660133, Russia
-
MFSMC-HJWCI-Oncology Research ( Site 0128)
Baltimore, Maryland, 21237, United States
-
Meir Medical Center ( Site 2601)
Kfar Saba, 4428164, Israel
-
Memorial Sloan Kettering Cancer Center ( Site 0115)
New York, New York, 10065, United States
-
N.N.Petrov Research Institute of Oncology-Department of Chemotherapy and Innovative Technologies ( S
Saint Petersburg, Sankt-Peterburg, 197758, Russia
-
Narodowy Instytut Onkologii im. Marii Sklodowskiej-Curie - P-Klinika Nowotworow Pluca i Klatki Pier
Warsaw, Masovian Voivodeship, 02-781, Poland
-
Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0122)
Omaha, Nebraska, 68130, United States
-
Oncology Hematology West, PC dba Nebraska Cancer Specialists ( Site 0129)
Omaha, Nebraska, 68130, United States
-
Országos Korányi Pulmonológiai Intézet-XIV. Tüdöbelgyógyászat ( Site 2806)
Budapest, Pest County, 1121, Hungary
-
Ospedale San Raffaele-Oncologia Medica ( Site 2303)
Milan, Lombardy, 20132, Italy
-
Parkview Research Center at Parkview Regional Medical Center ( Site 0130)
Fort Wayne, Indiana, 46845, United States
-
Perlmutter Cancer Center at NYU Langone Hospital - Long Island ( Site 0114)
Mineola, New York, 11501, United States
-
Rabin Medical Center-Oncology ( Site 2604)
Petah Tikva, 4941492, Israel
-
Rambam Health Care Campus-Oncology ( Site 2600)
Haifa, 3109601, Israel
-
Samodzielny Publiczny Zespó Grulicy i Chorób Puc w Olsztynie-Oddzial Onkologii z Pododdzialem Chemi
Olsztyn, Warmian-Masurian Voivodeship, 10-357, Poland
-
Samsung Medical Center ( Site 1100)
Seoul, 06351, South Korea
-
Scientific research institution of oncology named after N.N. Petrov-Thoracic oncology ( Site 2704)
Saint Petersburg, 197758, Russia
-
Semmelweis University-Pulmonológiai Klinika ( Site 2802)
Budapest, 1083, Hungary
-
Seoul National University Bundang Hospital ( Site 1104)
Seongnam, Kyonggi-do, 13620, South Korea
-
Seoul National University Hospital ( Site 1101)
Seoul, 03080, South Korea
-
Severance Hospital, Yonsei University Health System-Medical oncology ( Site 1105)
Seoul, 03722, South Korea
-
Shaare Zedek Medical Center ( Site 2602)
Jerusalem, 9103102, Israel
-
Sheba Medical Center-ONCOLOGY ( Site 2603)
Ramat Gan, 5262100, Israel
-
St Francis Cancer Center-Research Office ( Site 0117)
Greenville, South Carolina, 29607, United States
-
St. Marys Hospital Center ( Site 2000)
Montreal, Quebec, H3T 1M5, Canada
-
The Catholic University Of Korea St. Vincent's Hospital ( Site 1106)
Suwon, Kyonggi-do, 16247, South Korea
-
Torokbalint Tudogyogyintezet-Onkopulmonologiai Jarobeteg Centrum ( Site 2801)
Törökbálint, Pest County, 2045, Hungary
-
UPMC Hillman Cancer Center ( Site 0127)
Pittsburgh, Pennsylvania, 15232, United States
-
University of Colorado Anschutz Medical Campus ( Site 0104)
Aurora, Colorado, 80045, United States
-
Virginia Cancer Institute ( Site 0119)
Richmond, Virginia, 23229, United States
-
Zala Megyei Szent Rafael Kórház-Pulmonológia ( Site 2805)
Zalaegerszeg, Zala County, 8900, Hungary
-
ospedale le scotte-U.O.C. Immunoterapia Oncologica ( Site 2300)
Siena, Tuscany, 53100, Italy